Le groupe pharmaceutique Sanofi a annoncé mercredi que la Food and Drug Administration , l'autorité sanitaire américaine, ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

(Zonebourse.com) - Sanofi annonce que la FDA des États-Unis a accordé la désignation de médicament orphelin à SAR446523, son anticorps monoclonal expérimental anti-GPRC5D, pour le traitement potentiel ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

LaNova Medicines Ltd. a annoncé avoir conclu un accord de licence exclusif avec AstraZeneca pour le LM-305, un conjugué anticorps-médicament au stade préclinique ciblant le récepteur couplé ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific antibodies, ...

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices ...